Skip to content
10-Q

Quarterly Report

Ventyx Biosciences, Inc.

0000950170-25-066996

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 5, 2025 71.16M sh
Shares Diluted Q1 2025 · Mar 31, 2025 71.13M sh
Shares Diluted Q1 2025 · Mar 31, 2024 61.83M sh
Capex Q1 2025 · Mar 31, 2025 $16K
Capex Q1 2025 · Mar 31, 2024 $175K
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$25.72M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$47.63M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $28.08M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $27.26M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $141.9M
Stockholders Equity Q1 2025 · Mar 31, 2025 $231.63M
Stockholders Equity Q1 2025 · Dec 31, 2024 $254.05M
Stockholders Equity Q1 2025 · Mar 31, 2024 $307M
Stockholders Equity Q1 2025 · Dec 31, 2023 $243.92M
Current Liabilities Q1 2025 · Mar 31, 2025 $12.39M
Current Liabilities Q1 2025 · Dec 31, 2024 $12.78M
Total Liabilities Q1 2025 · Mar 31, 2025 $21.85M
Total Liabilities Q1 2025 · Dec 31, 2024 $22.52M
Current Assets Q1 2025 · Mar 31, 2025 $242.56M
Current Assets Q1 2025 · Dec 31, 2024 $229.63M
Total Assets Q1 2025 · Mar 31, 2025 $253.48M
Total Assets Q1 2025 · Dec 31, 2024 $276.56M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.39
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.62
Eps Basic Q1 2025 · Mar 31, 2025 −$0.39
Eps Basic Q1 2025 · Mar 31, 2024 −$0.62
Sga Expense Q1 2025 · Mar 31, 2025 $7.2M
Sga Expense Q1 2025 · Mar 31, 2024 $8.02M
Rd Expense Q1 2025 · Mar 31, 2025 $22.9M
Rd Expense Q1 2025 · Mar 31, 2024 $33.75M
Net Income Q1 2025 · Mar 31, 2025 −$27.44M
Net Income Q1 2025 · Mar 31, 2024 −$38.57M
Operating Income Q1 2025 · Mar 31, 2025 −$30.1M
Operating Income Q1 2025 · Mar 31, 2024 −$41.77M